PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?
BRCA1 Protein
/ genetics
BRCA2 Protein
/ genetics
DNA Repair
/ drug effects
Female
Genital Neoplasms, Female
/ drug therapy
Humans
Ovarian Neoplasms
/ drug therapy
Poly(ADP-ribose) Polymerase Inhibitors
/ administration & dosage
Uterine Cervical Neoplasms
/ drug therapy
Uterine Neoplasms
/ drug therapy
BRCA mutation
Cervical cancer
Gynecologic cancer
Homologous recombination repair
Ovarian cancer
PARP inhibitor
Uterine cancer
Journal
Current oncology reports
ISSN: 1534-6269
Titre abrégé: Curr Oncol Rep
Pays: United States
ID NLM: 100888967
Informations de publication
Date de publication:
17 02 2020
17 02 2020
Historique:
entrez:
19
2
2020
pubmed:
19
2
2020
medline:
24
6
2021
Statut:
epublish
Résumé
Conventional and novel applications of Poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors (PARPi) are reviewed in the context of recently published clinical trials and preclinical data supporting rapidly expanding uses of this class of chemotherapy. PARPi block a pathway of DNA repair and target defects in homologous recombination repair (HRR), a pathway responsible for high-fidelity repair of double-strand breaks in DNA. BRCA1/2 proteins are essential to this pathway. Approximately 15-30% of women with ovarian cancer will have a germline or somatic BRCA mutation, and PARPi have shown promise in this population in a variety of settings. With growing understanding of the HRR pathway and its role in gynecologic malignancies, the potential applications of PARPi continue to expand. While the role of PARPi in gynecologic malignancies is most established in ovarian cancer, there are also promising applications in uterine and cervical cancer. We review current indications for PARPi use and promising applications of these medications in gynecologic malignancies.
Identifiants
pubmed: 32067102
doi: 10.1007/s11912-020-0873-4
pii: 10.1007/s11912-020-0873-4
doi:
Substances chimiques
BRCA1 Protein
0
BRCA2 Protein
0
Poly(ADP-ribose) Polymerase Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
29Références
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S61-6
pubmed: 25341583
N Engl J Med. 2019 Dec 19;381(25):2403-2415
pubmed: 31562800
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
J Ovarian Res. 2019 Jan 28;12(1):9
pubmed: 30691488
Oncogene. 2018 Jan 18;37(3):341-351
pubmed: 28945226
Oncologist. 2019 Jul;24(7):973-979
pubmed: 30541756
N Engl J Med. 2014 Feb 20;370(8):734-43
pubmed: 24552320
Lancet Oncol. 2014 Oct;15(11):1207-14
pubmed: 25218906
Lancet Oncol. 2019 Apr;20(4):570-580
pubmed: 30880072
J Clin Oncol. 2015 Jan 20;33(3):244-50
pubmed: 25366685
Lancet Oncol. 2017 Jan;18(1):75-87
pubmed: 27908594
Sci Transl Med. 2010 Oct 13;2(53):53ra75
pubmed: 20944090
Gynecol Oncol. 2018 Feb 22;:
pubmed: 29477660
Gynecol Oncol. 2019 Oct;155(1):144-150
pubmed: 31434613
Gynecol Oncol. 1983 Feb;15(1):10-7
pubmed: 6822361
Nature. 2012 Jan 18;481(7381):287-94
pubmed: 22258607
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
BMC Cancer. 2017 Sep 8;17(1):638
pubmed: 28886696
Prz Menopauzalny. 2016 Mar;15(1):43-7
pubmed: 27095958
Lancet. 2016 Mar 12;387(10023):1094-1108
pubmed: 26354523
Cancer Discov. 2012 Nov;2(11):982-4
pubmed: 23148373
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Lancet Oncol. 2011 Sep;12(9):852-61
pubmed: 21862407
Nature. 2005 Apr 14;434(7035):913-7
pubmed: 15829966
Mol Cancer Ther. 2020 Jan;19(1):123-134
pubmed: 31597711
Curr Oncol Rep. 2005 Nov;7(6):419-34
pubmed: 16221379
Gynecol Oncol. 2012 Sep;126(3):424-7
pubmed: 22634397
N Engl J Med. 2012 Apr 12;366(15):1382-92
pubmed: 22452356
PLoS One. 2013;8(4):e60408
pubmed: 23565244
Oncotarget. 2019 Jul 02;10(42):4262-4275
pubmed: 31303961
Ther Adv Med Oncol. 2018 Jun 22;10:1758835918778483
pubmed: 29977351
Sci Rep. 2017 Oct 9;7(1):12876
pubmed: 28993682
J Clin Oncol. 2019 Jun 10;37(17):1470-1478
pubmed: 30943124
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
J Clin Oncol. 2012 Feb 1;30(4):372-9
pubmed: 22203755
Nat Rev Clin Oncol. 2011 May;8(5):302-6
pubmed: 21468130
Lancet Oncol. 2019 Oct;20(10):1409-1419
pubmed: 31474354
Jpn J Clin Oncol. 2019 Feb 1;49(2):108-120
pubmed: 30423148
Lancet Oncol. 2017 Sep;18(9):1274-1284
pubmed: 28754483
Ann Oncol. 2017 Mar 1;28(3):512-518
pubmed: 27993796
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
Best Pract Res Clin Obstet Gynaecol. 2017 May;41:3-14
pubmed: 27743768
Crit Rev Oncol Hematol. 2016 Dec;108:164-174
pubmed: 27931835